Sign up

Cormorant Asset Management, LP

$2.0B assets · 50 holdings · Q2 2026 · Filed 14 AUG 2026

About Cormorant Asset Management, LP’s 13F portfolio

Cormorant Asset Management, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Cormorant Asset Management, LP reported $2.0B across 50 US-listed positions (). Its largest position is PRAXIS PRECISION MEDICINES I (PRAX) at 11% of the reported book, and its ten biggest holdings make up 59% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$2.0B
Assets (13F)
#1,514
of 8,839 by size
50
Holdings
59%
Top-10 weight
17
Buys
37
Sells
Top holdings · Q2 2026
50 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: PRAX
PRAXIS PRECISION MEDICINES I
—
—
11%
640K$214.3M
2
NASDAQ: BBOT
BRIDGEBIO ONCOLOGY THERAPEUT
—
—
7.0%
17.9M$136.2M
3
NASDAQ: PBLS
PARABILIS MEDICINES INC
—
—
6.5%
4.6M$126.3M
4
NASDAQ: RAPP
RAPPORT THERAPEUTICS INC
—
—
5.7%
2.7M$110.7M
5
NASDAQ: ERAS
ERASCA INC
—
—
5.6%
6.0M$109.9M
6
NASDAQ: EWTX
EDGEWISE THERAPEUTICS INC
—
—
5.2%
2.5M$102.0M
7
NASDAQ: EYPT
EYEPOINT INC
—
—
5.1%
7.0M$100.1M
8
NASDAQ: ALMS
ALUMIS INC
—
—
4.7%
3.3M$92.5M
9
NASDAQ: ABVX
ABIVAX SA
—
—
4.6%
675K$90.0M
10
NASDAQ: DNTH
DIANTHUS THERAPEUTICS INC
—
—
3.7%
750K$73.1M
11
NASDAQ: DRUG
BRIGHT MINDS BIOSCIENCES INC
—
—
3.2%
900K$63.2M
12
NASDAQ: MLTX
MOONLAKE IMMUNOTHERAPEUTICS
—
—
3.2%
3.2M$62.4M
13
NASDAQ: BIOA
BIOAGE LABS INC
—
—
3.0%
2.4M$58.6M
14
NASDAQ: ORKA
ORUKA THERAPEUTICS INC
—
—
2.6%
533K$50.8M
15
NASDAQ: ANL
ADLAI NORTYE LTD
—
—
2.3%
4.0M$45.7M
16
NASDAQ: BBIO
BRIDGEBIO PHARMA INC
—
—
2.1%
550K$41.0M
17
NASDAQ: TNGX
TANGO THERAPEUTICS INC
—
—
2.1%
1.3M$40.6M
18
NYSE: BHVN
BIOHAVEN LTD
—
—
2.0%
2.6M$38.8M
19
NASDAQ: AGMB
AGOMAB THERAPEUTICS NV
—
—
1.6%
2.5M$32.0M
20
NASDAQ: MBX
MBX BIOSCIENCES INC
—
—
1.6%
550K$30.4M
21
NASDAQ: CLYM
CLIMB BIO INC
—
—
1.4%
2.1M$27.5M
22
NASDAQ: OLMA
OLEMA PHARMACEUTICALS INC
—
—
1.4%
2.1M$26.9M
23
NASDAQ: DMRA
DAMORA THERAPEUTICS INC
—
—
1.3%
1.0M$26.0M
24
NASDAQ: PHVS
PHARVARIS N V
—
—
1.3%
750K$25.9M
25
NASDAQ: CRBP
CORBUS PHARMACEUTICALS HLDGS
—
—
1.1%
2.3M$22.0M

Showing 1–25 of 50 positions on this page reported in this 13F.

Sector allocation
  • Healthcare88%
Recent activity · vs 2026-03-31
Bought17
  • NewPBLSPARABILIS MEDICINES INC—$126.3M
  • AddedERASERASCA INC+3.4%$109.9M
  • AddedANLADLAI NORTYE LTD+37.3%$45.7M
  • AddedBHVNBIOHAVEN LTD+48.3%$38.8M
  • NewCLYMCLIMB BIO INC—$27.5M
  • NewSYRESPYRE THERAPEUTICS INC—$20.0M
  • NewDFTXDEFINIUM THERAPEUTICS INC—$18.8M
  • NewASNDASCENDIS PHARMA A/S—$13.3M
  • NewKLRAKAILERA THERAPEUTICS INC—$12.1M
  • AddedSNSEFAETH THERAPEUTICS INC+236%$7.7M
Sold37
  • ReducedPRAXPRAXIS PRECISION MEDICINES I−27.7%$214.3M
  • ReducedRAPPRAPPORT THERAPEUTICS INC−10.1%$110.7M
  • ReducedEWTXEDGEWISE THERAPEUTICS INC−23.0%$102.0M
  • ReducedEYPTEYEPOINT INC−15.3%$100.1M
  • ReducedALMSALUMIS INC−16.8%$92.5M
  • ReducedABVXABIVAX SA−11.2%$90.0M
  • ReducedDNTHDIANTHUS THERAPEUTICS INC−21.1%$73.1M
  • ReducedDRUGBRIGHT MINDS BIOSCIENCES INC−15.0%$63.2M
  • ReducedMLTXMOONLAKE IMMUNOTHERAPEUTICS−28.5%$62.4M
  • ReducedBIOABIOAGE LABS INC−17.3%$58.6M
5%+ Beneficial Ownership Stakes · 1 activist (13D) · 13 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
BLSM
BlossomHill Therapeutics, Inc.
13D11.8%3.6MFiled 13 AUG 2026
2
CUE
Cue Biopharma, Inc.
13G10.0%791KFiled 16 NOV 2026
3
QNCX
Quince Therapeutics, Inc.
13G10.0%108KFiled 14 AUG 2026
4
CABA
Cabaletta Bio, Inc.
13G9.3%9.4MFiled 17 FEB 2026
5
DRUG
Bright Minds Biosciences Inc.
13G8.1% · 2 classes800KFiled 16 NOV 2026
6
CRBP
Corbus Pharmaceuticals Holdings, Inc.
13G7.8% · 2 classes1.5MFiled 02 NOV 2026
7
—
CARGO Therapeutics, Inc.
13G7.3%3.4MFiled 15 MAY 2025
8
ANL
Adlai Nortye Ltd.
13G6.8%4.0MFiled 14 AUG 2026
9
RAPP
Rapport Therapeutics, Inc.
13G6.3% · 2 classes3.0MFiled 17 FEB 2026
10
MLTX
MoonLake Immunotherapeutics
13G6.1%4.4MFiled 17 FEB 2026
11
ENGN
enGene Holdings Inc.
13G6.0%4.0MFiled 17 FEB 2026
12
BIOA
BioAge Labs, Inc.
13G5.7%2.0MFiled 17 FEB 2026
13
ETRA
Electra Therapeutics, Inc.
13G5.4%3.4MFiled 16 NOV 2026
14
AGMB
Agomab Therapeutics NV
13G5.0%2.5MFiled 15 MAY 2026

Showing all 14 disclosed stakes. 1 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Cormorant Asset Management, LP’s 13F portfolio

Cormorant Asset Management, LP’s $2.0B 13F book is spread across 50 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 59%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are PRAX, BBOT, PBLS, RAPP and ERAS, led by PRAXIS PRECISION MEDICINES I (PRAX) at 11% of the portfolio. The heaviest sector exposure is Healthcare (88%).

What Cormorant Asset Management, LP changed last quarter

Between 2026-03-31 and Q2 2026, Cormorant Asset Management, LP was a net seller: it opened 13 new positions and added to 4 more, while trimming 28 and closing 9 outright. Against a 50-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was PARABILIS MEDICINES INC (PBLS), and its biggest reduction was PRAXIS PRECISION MEDICINES I (PRAX).

What a 13F does and doesn’t reveal

A 13F captures only Cormorant Asset Management, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Cormorant Asset Management, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Cormorant Asset Management, LP's profile on this page is built directly from those filings.

How current is the 13F data on Cormorant Asset Management, LP's page?

It reflects Cormorant Asset Management, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Cormorant Asset Management, LP files its next quarterly report, this page refreshes automatically.

Can I see Cormorant Asset Management, LP's complete list of holdings?

This page highlights Cormorant Asset Management, LP's largest positions rather than all 50 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Cormorant Asset Management, LP's filings.

Does a 13F show everything Cormorant Asset Management, LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Cormorant Asset Management, LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Cormorant Asset Management, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.